Hepatitis is fatal disease of liver, and in Pakistan thousands of people suffering from the disease. The drugs for hepatitis are costly and the average Pakistani could not afford them , and they die as a consequence. A large quantity of interferon injection produced indigenously from researchers within Pakistan to help the most vulnerable patients who suffer from hepatitis will expire December of 2010 due to the lack of attitude of authorities. Research was conducted within the Centre of Excellence in Molecular Biology (CEMP) and Allama Iqbal Medical College (AIMC) in 2008, where interferon was reproduced to lower the price of the hepatitis. Hepatitis C is considered to be the number one killer disease in Pakistan and is primarily, if not exclusively people in the middle class and the poor. The group cloned Thuốc Hepbest 25mg interferon to allow it to be sold in the local market at the cost that is much lower than the price of imported vials of the injection. Import bill for interferon stood at in the range of Rs 1.1 billion in 2005 as well as Rs 1.4 billion in 2006 and Rs. 3 billion in 2009. Despite the massive spending only 5% of patients with hepatitis were diagnosed and treated, while 90% died. Recently all the brands are beyond the reach of poor people. The plan for the indigenous production of interferon has been pending with the federal health ministry and the Pakistan medical research council (PMRC). If it is not resolved, 100000 injections of interferon made in the last few years will expire on the 31st of March which will lead to the waste of research effort as well as the use of resources. Hepatitis C patients were required to take three injections per week. The treatment was carried out for between 6 and 18 months, depending on the intensity of the virus. On average, diagnosis and follow-up costs more than Rs 50000 per patient, and the total treatment costs ranging from up to 150,000 Rs. a dose of local intraferon cost Rs 70 whereas the price of the imported medicine was Rs 6000 to 9000. One researcher suggested that if and when it was discovered that this study, which resulted in the production in Pakistan of 18 pharmaceutical proteins from the United States, was allowed to reach the poor patient, Pakistan would benefit greatly in the shape of savings in foreign exchange and lessening the suffering of millions. Lahore High Court on 12 November 2010 issued notice in response to a an application was filed to have the health ministry be directed not to set up obstacles in the manufacturing of locally produced hepatitis medicine. Justice wanted a written reply from secretaries of health, science and technology as well as their executive directors of the Pakistan Medical Research Council. This is truly depressing since there are a lot of people suffering from Pakistan there are more than 12 million patients of Hepatitis and the government isn't doing enough for those people. After researches have had a successful low-cost medicine for poor, indifferent policy of the government is not permitting them to utilize.